Demant A/S (OTCMKTS:WILYY) Sets New 52-Week High – Here’s What Happened

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) reached a new 52-week high during trading on Tuesday . The company traded as high as $22.34 and last traded at $22.34, with a volume of 1400 shares traded. The stock had previously closed at $20.66.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on WILYY. Sanford C. Bernstein lowered shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Zacks Research upgraded Demant A/S to a “hold” rating in a research note on Friday, June 26th. Morgan Stanley upgraded Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Finally, UBS Group downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Demant A/S presently has a consensus rating of “Moderate Buy”.

Demant A/S Price Performance

The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. The stock has a 50 day moving average of $20.38 and a 200 day moving average of $17.40.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.